{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:48:58Z","timestamp":1784731738095,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Tulane Cancer Center"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.clgc.2019.10.022","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T11:35:07Z","timestamp":1573040107000},"page":"148-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"Lynne","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa M.","family":"Ledet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro C.","family":"Barata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Cotogno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Manogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce R.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Steinwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahiru","family":"Ranasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi L.","family":"Layton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8777-7343","authenticated-orcid":false,"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.10.022_bib1","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2019.10.022_bib2","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.18632\/oncotarget.26642","article-title":"Application of cell-free DNA for genomic tumor profiling: a feasibility study","volume":"10","author":"Ahlborn","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2019.10.022_bib3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2019.10.022_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","article-title":"Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others","volume":"15","author":"Sabapathy","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2019.10.022_bib5","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: one name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes Dev"},{"key":"10.1016\/j.clgc.2019.10.022_bib6","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.clgc.2019.10.022_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers?","volume":"25","author":"Baugh","year":"2018","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.clgc.2019.10.022_bib8","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1038\/srep04223","article-title":"Heterogeneity of Li-Fraumeni syndrome links to unequal gain-of-function effects of p53 mutations","volume":"4","author":"Xu","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.clgc.2019.10.022_bib9","first-page":"293","article-title":"Mutant p53 in cancer therapy\u2014the barrier or the path","volume":"11","author":"Zhou","year":"2019","journal-title":"J\u00a0Mol Cell Biol"},{"key":"10.1016\/j.clgc.2019.10.022_bib10","doi-asserted-by":"crossref","first-page":"e0140712","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2019.10.022_bib11","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","article-title":"Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies","volume":"24","author":"Odegaard","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.10.022_bib12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clgc.2019.10.022_bib13","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.clgc.2019.10.022_bib14","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1007\/s00018-017-2575-0","article-title":"Molecularly targeted therapies for p53-mutant cancers","volume":"74","author":"Zhao","year":"2017","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.clgc.2019.10.022_bib15","doi-asserted-by":"crossref","first-page":"41825","DOI":"10.18632\/oncotarget.6167","article-title":"Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer","volume":"6","author":"Chang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2019.10.022_bib16","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-18-1943","article-title":"TP53 outperforms other androgen receptor biomarkers to predict abiraterone or enzalutamide outcome in metastatic castration-resistant prostate cancer","volume":"25","author":"De Laere","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.10.022_bib17","doi-asserted-by":"crossref","first-page":"125529","DOI":"10.1172\/jci.insight.125529","article-title":"Multiparametric liquid biopsy analysis in metastatic prostate cancer","volume":"4","author":"Hodara","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.clgc.2019.10.022_bib18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41391-017-0027-4","article-title":"p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer","volume":"21","author":"Maughan","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2019.10.022_bib19","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clgc.2017.12.004","article-title":"Clinical variables associated with overall survival in metastatic castration-resistant prostate cancer patients treated with sipuleucel-T immunotherapy","volume":"16","author":"Wei","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2019.10.022_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2016.00123","article-title":"Very early PSA response to abiraterone in mCRPC patients: a novel prognostic factor predicting overall survival","volume":"7","author":"Facchini","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clgc.2019.10.022_bib21","doi-asserted-by":"crossref","first-page":"E30","DOI":"10.1111\/bju.13631","article-title":"Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer","volume":"120","author":"McDaniel","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2019.10.022_bib22","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-18-3401","article-title":"TP53 and prognosis in mCRPC survival: biology or coincidence?","volume":"25","author":"Rebello","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.10.022_bib23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/ijgc-2018-000087","article-title":"TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses","volume":"29","author":"Mandilaras","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.clgc.2019.10.022_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41418-018-0126-3","article-title":"TP53 gain-of-function mutation promotes inflammation in glioblastoma","volume":"26","author":"Ham","year":"2019","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.clgc.2019.10.022_bib25","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/1535-7163.MCT-17-0353","article-title":"TRP53 mutants drive neuroendocrine lung cancer through loss-of-function mechanisms with gain-of-function effects on chemotherapy response","volume":"16","author":"Akeno","year":"2017","journal-title":"Mol Cancer Ther"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731930326X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731930326X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:32:10Z","timestamp":1761564730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876731930326X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S155876731930326X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.10.022","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}